Navigation Links
PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
Date:2/3/2009

in a registration-directed pivotal study with the goal of demonstrating that allowing expression of a critical missing protein will safely provide clinical benefits for patients with nonsense mutation genetic disorders. Ataluren has been generally well tolerated across all clinical studies to date.

The FDA and the European Commission have granted PTC124 (ataluren) orphan drug status for the treatment of DMD and cystic fibrosis due to nonsense mutations. The FDA has also granted PTC124 (ataluren) Subpart E designation for expedited development, evaluation, and marketing.

PTC has an exclusive collaboration with Genzyme Corporation for the development and commercialization of ataluren. PTC Therapeutics will market ataluren in the United States and Canada, while Genzyme will commercialize the product in other regions of the world. The development of ataluren has also been supported by grants from the Muscular Dystrophy Association, Parent Project Muscular Dystrophy, FDA's Office of Orphan Products Development, the National Center for Research Resources and the Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation), which recently expanded support of ataluren to include funding up to $25 million.

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology, and infectious diseases. PTC has extensive knowledge of post-transcriptional control processes and has developed proprietary technologies that it applies in its drug d
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
2. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
3. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
4. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
7. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
8. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
9. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
10. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
11. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today ... 2015. Key results include: , Total revenues ... 2014 to $5,370 million, with 6 percent product ... (etanercept), Prolia ® (denosumab), Sensipar ® ... (denosumab). Unfavorable changes in foreign exchange rates ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... Bacterin International Holdings, Inc. ("Bacterin") (OTC Bulletin Board: ... present at the upcoming OneMedForumSF 2011, Emerging Company Finance Conference, ... the Sir Francis Drake Hotel in San Francisco, CA.  Guy ... Company,s operations and its strategic positioning. Bacterin, founded ...
... ARLINGTON, Va., Jan. 3, 2011 BNA Books ... publication of the Second Edition ... upon reference available with a detailed, practitioner-oriented treatment of pharmaceutical ... the food and drug laws. (Logo: http://photos.prnewswire.com/prnh/20090529/DC24463LOGO ...
Cached Medicine Technology:Bacterin International Holdings to Present at the OneMedForum San Francisco 2011 2Bacterin International Holdings to Present at the OneMedForum San Francisco 2011 3New Second Edition of Pharmaceutical Patent Law Examines Critical Intersection of Patent Law and Food and Drug Law 2New Second Edition of Pharmaceutical Patent Law Examines Critical Intersection of Patent Law and Food and Drug Law 3
(Date:8/1/2015)... ... , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was ... National Retail Federation, the largest retail trade association in the world, for her “advocacy ... to be named as such. According to the NRF’s website, Retail Champions are “Main ...
(Date:8/1/2015)... TX (PRWEB) , ... August 01, 2015 , ... BeverlyD, ... for the March4thforWellBeing foundation, making hers the very first small business donation to kick ... look beautiful for over thirty years. Her legacy includes a complete line of raw, ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 ... ... the five new industry players to know in predictive health analytics , ... machine learning technologies. The firm creates predictive software that targets patient and population ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... an important workshop at its new True North Conference Center. The medical community, ... that the Jacksonville community may be more aligned in the effort to better ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... in Canadian hospitals, way beyond estimation, raising concern among ... investigator in the study said, “The stark reality in ... and other drug-resistant bacteria are posing a serious threat ... these super bugs are more likely to have longer ...
... a drug charity has revealed that young men are ... looks as well as to boost their self-confidence.// ... body builders and athletes to improve their performance, were ... building site workers between the ages 16 and 25. ...
... been developed by a researcher from Cornell University that detects ... in food processing.// , ‘It’s very inexpensive, it ... and it could be activated for whatever you want to ... Professor of Fibre Science and Apparel Design at Cornell. ...
... next week the distribution of a drug to help fight ... Africa is being affected by an extremely virulent strain of ... in the country. The health officials have now promised that ... next week to help fight the disease. The officials but ...
... properly for their safety and efficacy, says a ... // The drugs that are being indiscriminately prescribed ... ,The researchers analyzed drugs covered by a "congressionally ... the Food and Drug Administration (FDA) may extend ...
... branded inhalation capsules in India for the treatment of ... Beta2-agonist Formoterol and the most potent inhaled corticosteroid Fluticasone, ... 100 mcg, Avessa 250 mcg, Avessa 500 mcg, depending ... product is to be used only with the Rheohaler ...
Cached Medicine News:Health News:Nanotech Wipes for biohazard detection 2Health News:South Africa To Make Available Two New Drugs To Fight The TB Outbreak 2Health News:Doctors Unaware If Pediatric Dosages Are Safe 2Health News:Doctors Unaware If Pediatric Dosages Are Safe 3
... Durable ergonomic chairs with concave seats ... Select options like seats, backrests, armrests, and ... Series for top performance in a variety ... room, static control, health care and office. ...
... Durable ergonomic chairs with concave seats and ... options like seats, backrests, armrests, and casters ... for top performance in a variety of ... static control, health care and office. • ...
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
Medicine Products: